Poland· PL-100474509
Axhidrox
A glycopyrronium product containing glycopyrronium, registered in Poland by Dr. August Wolff GmbH & Co. KG Arzneimittel. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Glycopyrronium is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AA01 (glycopyrronium), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Glycopyrronium · ATC D11AA01
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Glycopyrronium
- Manufacturer
- Dr. August Wolff GmbH & Co. KG Arzneimittel
- Country
- Poland (PL)
- ATC code
- D11AA01
- ATC class
- Glycopyrronium
- Defined daily dose
- 8.8 mg, T
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991516673
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
108 interactions on record for glycopyrronium.
Graded by severity as the source publishes them — 107 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glycopyrronium · interactions on record
108 records
- 107 moderate
- 1 minor
Most severe, free to view
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- MepenzolateA03AB12moderate
- TrospiumA03AB20moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glycopyrronium in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandAxhidrox 2,2 mg/Hub, CremeGebro Pharma AG
- SpainAXHIDROX 2,2 MG/PULSACION CREMAIndustrial Farmaceutica Cantabria S.A.
- SwedenGlycopyrronium Cantabria 2,2 mg/pumpning KrämIndustrial Farmaceutica Cantabria S.A.
- NetherlandsAxhidrox 8 mg/g, crèmeEuro Registratie Collectief B.V.
- ItalyGLICOPIRRONIO DOCDOC GENERICI S.R.L.
- IcelandEnurev BreezhalerNovartis Europharm Limited*
- United StatesQbrexzaJourney Medical Corporation
- GermanyRybrilaColonis Pharma B.V.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Austria · Rybrila
- Germany · Rybrila
- Spain · Axhidrox
- Sweden · Glycopyrronium Cantabria
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a9372596-1524-4c5d-b698-4fe41756e6c7 GET /v1/drugs/a9372596-1524-4c5d-b698-4fe41756e6c7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Krem",
"source": "urpl",
"strength": "2,2 mg/dozę",
"packaging": "05909991516673 ¦ Rp ¦ 150425\n1 pojemnik 50 g",
"substance": "Glycopyrronium 2,2 mg/dozę",
"common_name": "Glycopyrronium",
"pl_product_id": "100474509",
"pozwolenie_nr": "27903",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about glycopyrronium.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.